Hosiriluck Nattamol, Rassameehiran Supannee, Argueta Erwin, Tijani Lukman
Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.
Proc (Bayl Univ Med Cent). 2014 Oct;27(4):361-3. doi: 10.1080/08998280.2014.11929160.
Sickle cell intrahepatic cholestasis (SCIC) is a rare but fatal complication of sickle cell disease. It is found mainly in homozygous sickle cell disease. To date, there are no standard diagnostic criteria or well-established therapeutic approaches to this condition. Herein, we report this case of a 48-year-old man with sickle cell anemia and a total bilirubin of 78.5 mg/dL without evidence of extrahepatic biliary obstruction or viral hepatitis. The patient had a hemoglobin S level of 87.9%, acute renal failure, and mild coagulopathy. Despite the disease severity, he refused exchange transfusion (ET) with packed red blood cells. He was transfused with 2 units of blood and treated mainly with supportive measures. His total bilirubin levels trended down to normal days after discharge. Multiple studies have shown a significant decrease in the mortality rate in SCIC after ET. To date, only two reported adult cases have survived SCIC without aggressive treatment. Our case is the third case that demonstrates recovery of severe SCIC without ET.
镰状细胞性肝内胆汁淤积症(SCIC)是镰状细胞病一种罕见但致命的并发症。它主要见于纯合子镰状细胞病。迄今为止,对于这种病症尚无标准的诊断标准或成熟的治疗方法。在此,我们报告一例48岁患有镰状细胞贫血且总胆红素为78.5mg/dL的男性病例,该病例无肝外胆管梗阻或病毒性肝炎的证据。患者血红蛋白S水平为87.9%,伴有急性肾衰竭和轻度凝血功能障碍。尽管病情严重,但他拒绝接受红细胞置换输血(ET)。他接受了2单位血液的输血治疗,主要采用支持性措施进行治疗。出院数天后,他的总胆红素水平降至正常。多项研究表明,ET后SCIC的死亡率显著降低。迄今为止,仅有两例报告的成年病例在未进行积极治疗的情况下从SCIC中存活下来。我们的病例是第三例显示在未进行ET的情况下严重SCIC得以康复的病例。